FAST NEWS: WuXi Biologics boosts new projects target
The latest: Contract drug services provider WuXi Biologics (Cayman) Inc. (2269.HK) announced on Wednesday it has raised its guidance for new projects in 2024 from 80 to 110, despite a…
Cash-strapped Viva Biotech sells stake and plans spinoff
The biotech has gained a capital injection from Temasek and a major Chinese investor, but the deal has not boosted investor confidence Key Takeaways： As well as tapping strategic investors,…
FAST NEWS: Wuxi Bio Dives after Major Stakeholder Sells Shares
The latest: Contract drug services provider WuXi Biologics (Cayman) Inc. (2269.HK) announced on Tuesday that Biologics Holdings, one of its substantial shareholders controlled by its Chairman Li Ge, sold 56…
FAST NEWS: WuXi Biologics Announces $300 Million Share Buyback
The latest: Contract drugs services provider WuXi Biologics (Cayman) Inc. (2269.HK) announced on Monday its board of directors has approved a plan to buy back up to $300 million of the…
Viva Biotech Dispenses Bitter Pill of Slowing Growth, Asset Devaluation
The contract drug services provider lost roughly 100 million yuan in the first half of this year, as its revenue growth underperformed its peers Key Takeaways: Viva Biotech’s eked out…
Buoyed by Bumper Profits, WuXi Biologics Seeks to Bolster Global Supply Chain
Drugs services provider WuXi Biologics has issued a positive earnings alert for the first half of the year, predicting revenue would rise by up to 63% and net profit would…
FAST NEWS: Viva Biotech Finds First Profits in Drug Research Services
The latest: Viva Biotech Holdings (1873.HK) announced it earned a net profit of 287 million yuan ($45 million) last year, reversing a 386 million yuan loss in 2020, equating to earnings of…
Recent Articles
RELATED ARTICLES
-
U.S. rethinks timing of biotech crackdown, easing pressure on WuXi family
2269.HK 2359.HK 2268.HK -
WuXi Bio prescribes share buyback to relieve revenue pain
2269.HK
-
Potential U.S. targeting casts shadow over WuXi AppTec family
2359.HK 603259.SHG
-
WuXi AppTec posts lower profits but avoids more share price pain
2359.HK 603259.SHG
-
WuXi AppTec mulls gene unit sale to soften U.S. legal blow
2359.HK 603259.SHG
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
China-focused Tigermed staves off biopharma gloom
3347.HK 300347.SHE
